PDUFA day for Camurus Oclaiz octreotide depot, Wegovy pill hits 3M US scripts in 5 months, Lantheus PNT2003 stay expires, and the peptide-enforcement watch.
Read digest →Post-ADA: Pfizer's monthly berobenatide hits 15.9%, retatrutide's dysesthesia signal sharpens to 20.9% at 12 mg, analysts read Lilly dominant and Roche me-too.
Read digest →ADA closes: orforglipron beats oral semaglutide head-to-head, elecoglipron 10.5%, Roche enicepatide 22.5%, survodutide fat-loss detail, plus new SoC.
Read digest →ADA Day 3: REIMAGINE 1/2/3 publishes in Lancet, mazdutide beats semaglutide head-to-head, zenagamtide hits 14.6% in T2D, elecoglipron and MetaVia add detail.
Read digest →ADA Day 2: full retatrutide TRIUMPH-1 + TRIUMPH-4 data, Lancet publishes TRANSCEND-T2D-1, an arrhythmia signal, plus the ADA Obesity Standards of Care.
Read digest →ADA opens: Structure aleniglipron in Nature Medicine, CagriSema REIMAGINE 2 14.2% T2D loss, survodutide SYNCHRONIZE-1, Hengrui HRS-7535, MetaVia, Lexicon.
Read digest →ADA's eve: Parabilis prices a $476M peptide IPO, plus pre-conference data from petrelintide, survodutide, Verdiva, and elecoglipron.
Read digest →Two days before ADA 2026: Novo's CagriSema and zenagamtide slate, Structure's oral aleniglipron, an EPFL cyclic-peptide advance, and the field preview.
Read digest →A STAT/Undark BPC-157 evidence probe, an MC4R-deficiency GLP-1 comparison, Sapience's lucicebtide ASCO data, the ADA 2026 preview, and Camurus' June 10 PDUFA.
Read digest →ASCO's biggest peptide-oncology day: Bicycle, Mayo TPIV200, Avacta and Pfizer sigvotatug, plus Syneron's $150M peptide raise and Lilly's ADA slate.
Read digest →Orforglipron maintains weight loss after switching off injectables, Perspective's lead-212 radioligands and BioVaxys' survivin vaccine reach ASCO, BriaCell raises $4.7M.
Read digest →ASCO Day 2 + EASL close: Immutep eftilagimod 7.7-month survival gain, ImPact padeliporfin pancreatic Phase 1, EASL HBV functional-cure late-breakers, copper-peptide cosmetics.
Read digest →ASCO opens + EASL closes: Corbus CRB-701 42.9% OPSCC, Telix ProstACT PSMA, MetaVia DA-1726 9.1% weight loss, BriaCell CAML biomarker, Aligos HBV, GLP-1 breast cancer.
Read digest →EASL Day 2: pemvidutide 48-week oral data, survodutide NEJM MASH 47-62%, Aligos ALG-055009 46% liver fat, Mayo folate-receptor vaccine TNBC, Roswell GLP-1 breast cancer.
Read digest →EASL Day 1: pemvidutide qFibrosis LBP-036, DA-1726 48 mg, ARO-INHBE 44% liver fat, ESSENCE Japanese/menopausal, Rezdiffra Day 1, NeoVax GBM, Aktis AKY-2519.
Read digest →ASCO GLP-1 cancer metastasis 12,112 patients, Oorja Bio launch ORJ-001 IPF, Altimmune Best of EASL pemvidutide, ASCO press briefing 3:30 PM ET, Zealand Pharma EGM.
Read digest →Gilead's Hepcludex (bulevirtide) FDA accelerated approval — first US treatment for chronic HDV, Altimmune pemvidutide EASL fibrosis regression, Madrigal Rezdiffra portal hypertension.
Read digest →Wegovy HD 7.2 mg CHMP positive opinion, Foundayo Week 6 IQVIA ~17K vs Wegovy pill ~142K, ASCO May 26 embargoed press briefing, Memorial Day dual-meeting week.
Read digest →